SLC5A2 and chronic kidney disease: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown efficacy not only in patients with diabetic kidney disease but also in those with non-diabetic CKD, demonstrating significant reductions in renal and cardiovascular outcomes [14].